Home Authors Posts by Kirk Falconer

Kirk Falconer

Fund IV is expected to soon hit 80 pct committed, suggesting Dyal could be back on the fundraising trail in the near future
Locke, who assumed the new role in June, is operating from CPPIB’s office in San Francisco, which opened earlier in 2019
The target for Fund VI was disclosed by France's Eurazeo, which last year acquired a minority stake in Rhône.
Valor Equity Partners V is expected to maintain the Chicago-based private equity firm's 18-year strategy. If the fund meets its $1.25 billion goal, it will be Valor's largest to date.
OMERS Private Equity has recruited Jeff French as a director in its office in Singapore, Buyouts has learned. French joins from Blackstone Group, where he worked for more than six years as a PE investment professional. French operated from Blackstone’s Singapore office with a focus on deal activity in the Asia-Pacific region.
healthcare, technology, health insurance, payers, medical, private equity
Persistence Capital Partners Fund III, which is targeting C$225 million ($170 million), is expected to wrap up in the first half of 2020, a source said. Initial fund commitments came from a range of limited partners, including both new and returning Canadian institutions.
James Aw, OMERS
OMERS hired James Aw to serve in the newly created position of chief medical officer, a person with knowledge of the matter told Buyouts. He will work with in-house teams to support OMERS’ human resources, members services and investment objectives, the source said.
JLL Partners has collected more than $686 million for its eighth flagship buyout fund, according to a Form D fundraising document. The amount raised, which reflects commitments from 53 limited partners, accounts for 55 percent of the $1.25 billion target set for JLL Partners Fund VIII.
New York firm's latest mid-market fund hit hard cap in less than four months.
Émond has taken on the role at Caisse de dépôt et placement du Québec following the departure of Stephane Etroy.

Copyright PEI Media

Not for publication, email or dissemination